RT Journal Article
SR Electronic
A1 Boltz, Kathy
T1 Immunotherapy Is Evolving and Promising for Lung Cancer
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 8
SP 28
OP 29
DO 10.1177/1559897715588457
UL http://mdc.sagepub.com/content/15/8/28.abstract
AB Checkpoint inhibitors have clear evidence of activity against programmed cell death and programmed death ligand in non–small cell lung cancer. Immunotherapies are increasingly being investigated in combinations, though strong immune responses warrant caution. Current therapeutic vaccines have had limited success in lung cancer. Clinical trial strategies are developing to best test targeted therapies.